BI Asset Management Fondsmaeglerselskab A S Raises Stock Position in Insulet Corporation $PODD

Key Points

• BI Asset Management Fondsmaeglerselskab A S raised its stake in Insulet Corporation by 60% in Q1, now owning 13,876 shares valued at approximately $3.64 million.
• Insulet's latest earnings report shows $1.17 earnings per share, surpassing estimates, with revenue increasing by 32.9% year-over-year.
• Wall Street analysts maintain a consensus rating of "Moderate Buy" for Insulet, with an average target price of $330.71.

BI Asset Management Fondsmaeglerselskab A S raised its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 60.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,876 shares of the medical instruments supplier's stock after purchasing an additional 5,202 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in Insulet were worth $3,644,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Larson Financial Group LLC increased its position in shares of Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after acquiring an additional 81 shares during the period. Zions Bancorporation National Association UT purchased a new position in shares of Insulet during the first quarter worth approximately $26,000. SouthState Corp increased its position in shares of Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 76 shares during the period. Itau Unibanco Holding S.A. purchased a new position in shares of Insulet during the fourth quarter worth approximately $42,000. Finally, Ramirez Asset Management Inc. purchased a new position in shares of Insulet during the first quarter worth approximately $53,000.

Insulet Stock Up 0.9%

PODD traded up $2.92 during trading on Friday, hitting $330.77. The stock had a trading volume of 499,504 shares, compared to its average volume of 705,185. The company has a market capitalization of $23.28 billion, a PE ratio of 100.54, a PEG ratio of 2.77 and a beta of 1.35. Insulet Corporation has a twelve month low of $180.31 and a twelve month high of $334.18. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The stock has a 50 day simple moving average of $300.94 and a two-hundred day simple moving average of $285.91.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. During the same period last year, the firm earned $0.55 earnings per share. Insulet's revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on PODD. Jefferies Financial Group reissued a "buy" rating on shares of Insulet in a report on Thursday, August 7th. Citigroup reissued a "buy" rating on shares of Insulet in a report on Tuesday, July 8th. Barclays lifted their price objective on shares of Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a report on Thursday. Royal Bank Of Canada lifted their price objective on shares of Insulet from $330.00 to $350.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Finally, Wall Street Zen raised shares of Insulet from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Sixteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $332.71.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.